Biomatter announced on November 12, 2026, that it had closed an oversubscribed $18 million Series A led by Astanor, with participation from existing investors UVC Partners, Inventure and Metaplanet. The company will use the financing to expand its AI-powered enzyme-design work and commercial operations. A central part of that expansion is a 2,000-square-meter design-and-testing facility in Vilnius, which Biomatter plans to open in 2027. The site will bring more laboratory building and testing…
This article has been indexed from Unite.AI
Read the original article:
Biomatter Raises $18M Series A to Expand AI Enzyme Design and Testing